Introduction
While the cause of multiple sclerosis (MS) remains unsolved, it is widely accepted that MS is autoimmune in nature. Inflammatory leukocytes are believed to infiltrate the central nervous system (CNS) to mediate the initiation and maintenance of disease leading to tissue damage involving both demyelination and neuronal degeneration. After invasion, these activated immune cells produce soluble mediators such as cytokines and vasoactive substances. Cytokines are a heterogeneous family of small secreted soluble polypeptides released by different cell types to have a specific effect on the communication and interaction between cells. 1 They are secreted by a number of different immune cells, including macrophages, lymphocytes, and mast cells, as well as other cells resident in the CNS, for example, endothelial cells. 2 Cytokines show redundancy in their activity, whereby identical functions can be induced by different cytokines. They are usually released in a cascade as one cytokine causes its target cells to produce other cytokines.
In MS, T cells and antigen-presenting cells (APCs) are key players during the inflammatory process. While APCs provide T cells with their cognate antigen and create a specific cytokine milieu, T cells use cytokines to maintain their function and polarization in an autocrine manner and regulate immune responses of various cell types. This process finally leads to particular cytokine signatures associated with specific T cell subsets that destroy blood-brain barrier integrity, resulting in inflammation, demyelination, and neuronal damage. 3 Translating these complex cytokine networks from commands like "destroy" or "degrade" to "arrest" or "tolerate" is the most difficult task for therapeutic strategies that influence and adapt cytokine-mediated communication. To delineate the role of individual cytokines in MS, we rely on preclinical experimental animal models such as experimental autoimmune encephalomyelitis (EAE).
In this review, we will present an overview of cytokines believed to contribute to the development of MS and provide examples demonstrating the complex networks and the challenges of translating data obtained from EAE to MS.
receptors (TNFR1 and TNFR2) with different affinities. Transmembrane TNF-α predominantly binds TNFR2, activating genes for cell survival and resolution of inflammation, while soluble TNF-α primarily acts through TNFR1, thereby mediating apoptosis and chronic inflammation. 4 TNFR1 is expressed on all cell types, whereas TNFR2 can be mainly found on neurons, endothelial, and immune cells. 5 Under beneficial homeostatic conditions, low levels of TNF-α support defense against pathogens, immune regulation, and inhibition of tumor growth. However, pathogenic function associated with higher levels of TNF-α includes facilitation of inflammation and thus tissue damage. 6 There is a large amount of evidence indicating a role for TNF-α in MS: increased levels of TNF-α can be found in active lesions within the CNS as well as in the serum and cerebrospinal fluid (CSF) of MS patients. Increased TNF-α in CSF also correlates with the severity and progression of disease. 2, 7 These strong indicators were supported by the successful treatment strategy of blocking TNF-α in mouse models of MS. 3 Subsequently, clinical trials with the TNF-α blockers infliximab and lenercept (a recombinant TNFR1 fusion protein) were initiated with unexpected, unfavorable results. 8, 9 Patients in these trials surprisingly suffered from increased disease activity (see Table 1 ). This suggests that non-selective blockade of TNF-α is harmful in MS, as TNF-α exerts both proinflammatory effects and protective functions, for example, mediating remyelination in the CNS under pathological conditions. 5, 40 Interleukin-6 in MS Interleukin-6 (IL-6), a potent inducer of the acute phase response, is secreted by T and B cells, macrophages, microglia, and also non-immune cells such as endothelial cells or neurons. 41 In contrast, its receptor is only found on a few cell types, including some leukocytes and microglia. However, a soluble IL-6 receptor (IL-6R) also exists that forms a complex with IL-6. This complex induces downstream signaling by binding to its β-receptor glycoprotein 130 (gp130), a protein almost ubiquitously expressed on many cell types, including astrocytes and neurons. 41 This socalled trans-signaling is critical for the proinflammatory properties of IL-6, while classical IL-6R signaling seems to be anti-inflammatory. Increased levels were found in active plaques of individuals suffering from MS. 21 IL-6 was further highlighted after the discovery that IL-6-deficient animals were fully resistant to EAE. 22 Furthermore, treatment with an IL-6R-blocking antibody or inhibition of trans-signaling in the periphery led to diminished, but not completely abolished symptoms in EAE. 41 While the findings were first believed to be the result of a shift from type 1 T-helper (T H 1) cells to type 2 (T H 2), it was later shown that IL-6-deficient animals are defective in T H 17 differentiation, 42 and the observed effects were attributed to downregulation of this novel T H subset. Furthermore, it was shown that IL-6 controls the balance between T H 17 and regulatory T cells (T regs ). 43 However, the importance of T H 17 could not be confirmed in further animal studies as discussed below.
Interestingly, current studies using transgenic mice suggest that the production of IL-6 in the CNS alone is sufficient to induce autoimmune processes in the absence of peripheral IL-6. 44 However, while transsignaling seems to be pivotal for such processes, 45 it was shown that this is not true for EAE. 41 Furthermore, a current study described a patient with rheumatoid arthritis who developed MS during anti-IL-6 therapy. 46 Given these findings, the role of IL-6 may not be purely detrimental in MS.
IL-12 and IL-23
IL-12 and IL-23 are both members of the so-called IL-12 family. Both cytokines are mainly secreted by activated APCs such as dendritic cells (DCs) or macrophages, thereby priming naïve CD4 + T cells to differentiate into cytokine-producing T H subsets. 47 While both cytokines are heterodimeric and share the socalled common IL-12p40 subunit, they pair with different subunits, respectively (IL-12p35 for IL-12 and IL-23p19 for IL-23). 2 As both cytokines share the IL-12p40 subunit, IL-12 and IL-23 are both able to interact with the IL-12 receptor β1 subunit. IL-12 interacts with IL-12R β1 and IL-12R β2 subunits, whereas IL-23 interacts with IL-12R β1 and IL-23R.
The high-affinity IL-12 receptor is expressed on activated T cells, natural killer (NK) cells, and DCs, while the IL-23 receptor is mainly expressed on activated T cells, T H 17, γδ T cells, natural killer T (NKT) cells, and lymphoid cells. 47 IL-12 is a master-regulator in the polarization of T H 1 cells, a pathogenic T H subset that has been implicated in driving the development of autoimmune disorders. 2 This view was supported by the finding that elevated IL-12 levels are observed in the CSF and lesions of MS patients. 27 Studies in mice also revealed significant increases in IL-12 and T H 1 levels in the course of EAE. T H 1 cells produce IL-2 (discussed below), TNF-α, and interferon γ (IFN-γ). Since myelin-specific T H 1 cells are effective in inducing EAE, MS research focused for a long time on this cell type. However, IFN-γ deficiency or pharmacological blockade of IFN-γ or its receptor led to a more severe clinical EAE phenotype, suggesting that IFN-γ could actually be protective. 48 However, administration of IFN-γ to individuals suffering from MS caused aggravation of the disease. 17 These results indicate that the differentiation pathway might be more important than the T H 1 cells themselves.
In this line, the relevance of IL-12 was evaluated in EAE. However, while deficiency of IL-12p40 or treatment with a neutralizing anti-p40 antibody of mice led to full protection from EAE, it was found that IL-12p35-deficient animals were even hypersusceptible, and that IL-12p35 can be used as therapeutic agent, thereby dismissing a central role of the IL-12-T H 1 axis in neuroinflammation. 2, 26, 49 This highlighted a fundamental role of IL-23, finally proven by the resistance of IL-23p19-deficient animals to EAE. 36 However, an anti-IL12p40 antibody called ustekinumab, used in a phase II clinical trial of relapsing-remitting multiple sclerosis (RRMS), revealed disappointing results with no significant therapeutic benefit. 28 A possible explanation for this failure might be poor CNS availability or that alternative proinflammatory pathways in MS are more important and are not affected.
Nonetheless, IL-23 is considered to be an essential cytokine in the development and maintenance of the newly identified T H 17 subset. 50 Besides IL-17A and IL-17F, T H 17 cells also produce cytokines such as IL-6, IL-21, IL-22, granulocyte-macrophage colonystimulating factor (GM-CSF), and TNF-α. 2, 50 T H 17 cells originate from naïve T cells in the presence of the cognate antigen and an environment rich of tumor growth factor beta (TGF-β) and IL-6 or IL-21; IL-23 is needed in vivo for generation, maintenance, and encephalotrophism. 51 Interestingly, circulating IL-17 and IL-22-secreting CD4 + T cells were shown to be increased in MS patients and even correlated with active brain lesions. 30 However, despite this clear link, neutralization of IL-17 by antibodies or IL-17 deficiency led only to a partial reduction of EAE symptoms. 52 These data suggest that terminal cytokine production by activated T cells, although being an easy addressable therapeutic target was not the determining factor for disease development as other proinflammatory mediators like GM-CSF might take over. Nonetheless, a current clinical study with an anti-IL-17 antibody revealed reduced lesion activity in magnetic resonance imaging (MRI) of MS patients 31 and transcriptome analysis of myelin-specific, encephalitogenic CCR6 + T cells from MS patients showed gene signatures reminiscent of EAE-induced pathogenic T H 17 cells. 11
Interferon beta IFN-β was identified in 1957 as a protective cytokine that regulates inflammation. 2 Years later, studies in EAE also revealed that IFN-β can suppress immunemediated demyelination. 13 In line with these observations, IFN-β1b was the first approved drug for individuals suffering from MS, reducing the severity and frequency of relapses and disease progression. 14 Until today, it remains a first-line treatment strategy for patients suffering from RRMS ( see Table 1 ). However, the mechanism of action was largely unknown. Nowadays, it is postulated that IFN-β acts primarily on myeloid cells 53 (see Figure 1) , and by limiting the production of other cytokines, exogenous IFN-β might exert its beneficial effects. This finding will possibly help in guiding the improvement of IFN-β-mediated immune modulation in the future.
IL-2, IL-9, and IL-21
IL-2, IL-9, and IL-21 are members of the common γ-chain family. 54 While IL-2 is predominantly produced by activated CD4 + T cells, IL-21 can be released by several cell types, such as T H 17, T H 2, and NKT cells. 32, 55 IL-9 is predominantly released by T H 9 and in smaller amounts by T H 17. 23 IL-2 binds to a high-affinity receptor complex consisting of three subunits designated as IL-2Rα (CD25), IL-2Rβ (CD122), and the common γ-chain (CD132). In the absence of the IL-2Rα subunit, the remaining subunits can form a receptor with intermediate affinity. However, the highaffinity receptor appears to be the only physiologically relevant form. 55 The IL-21 receptor constitutes a complex with the common γ-chain and a β-chain that exhibits homology with the IL-2 receptor.
IL-2 is a so-called T cell growth factor as it induces T cell expansion in vitro, building the basis for therapeutic strategies in AIDS and in preventing the rejection of transplanted organs. However, mice lacking IL-2 or its receptor were not immunocompromised, but instead developed severe autoimmune diseases. 55 It could be shown that IL-2 and its receptor play a key role in proliferation of autoreactive T cells and loss of immune tolerance in MS. In line with this finding, a monoclonal antibody (daclizumab) against the unique IL-2Rα subunit was developed, representing a new treatment option for MS. 19 IL-9-producing T H 9 cells generated in the presence of IL-4 and TGF-β are the newest addition to the T H cell family, meaning their functional role is currently not fully understood. 23 IL-9 is a pleiotropic cytokine affecting multiple cell types in the immune system (macrophages, T and B cells) and in the CNS (astrocytes, oligodendrocytes, and neurons). So far, there is some evidence that IL-9 can play a regulatory role in CNS autoimmunity and has a reciprocal relationship with T H 17. However, T H 9 generated in vitro can induce EAE, and thus the role of IL-9 in the pathogenesis of MS remains elusive with further studies needed for clarification. 23 IL-21 regulates the function of different immune cells. It enhances IFN-γ secretion and the cytotoxic function of NK and CD8 + effector T cells, affects survival of B cells, stimulates antibody production, inhibits the differentiation of inducible T regs , and leads to the expansion of T H 17 cells. In MS, it was shown that expression of IL-21 and its receptor are significantly increased on CD4 + T cells. 33 However, other studies revealed no differences in IL-21 levels in CSF and serum in MS patients in comparison to healthy individuals. 32, 34 In mice, different investigators showed that deficiency or pharmacological blockade of IL-21 or its receptor lead to an attenuated disease course in EAE with reduced numbers of T H 17 cells and expansion of T regs . However, contradictory studies also exist that reveal opposite results. 32 Nonetheless, therapeutic approaches in MS patients indicate a role for IL-21. For instance, treatment of MS patients with alemtuzumab (a CD52 antibody) or ultraviolet B (UVB) phototherapy led to decreased IL-21 levels. 32 All these discrepancies may be due to the fact that IL-21 is highly pleiotropic, meaning further studies are required to clarify the precise role of the IL-21 axis in MS.
IL-10 and IL-22
IL-10 and IL-22 belong to the IL-10 cytokine family with an α-helical secondary structure. 56 57 In MS patients, it is known that IL-10 secretion is decreased prior to relapse and increased during remission. In line with this, IL-10-deficient animals develop a more severe and accelerated EAE with a stronger proinflammatory immune response, suggesting that IL-10 plays a crucial role in recovery. Likewise, IL-10-overexpressing mice are highly resistant to EAE. However, therapeutic usage of IL-10 has revealed conflicting results. More promising results have been revealed with IL-10 gene therapy. Future studies including clinical trials will evaluate the efficacy of IL-10-based therapies for the treatment of MS. 57 In contrast to IL-10, IL-22 reveals proinflammatory properties. 56 There is evidence that serum IL-22 levels are increased and T H 22 cells were activated in MS patients during relapse. However, mice under IL-22 blockade were fully susceptible to EAE, 35 indicating again a redundancy of cytokine function of activated T cells (see Table 1 ).
GM-CSF
GM-CSF is a monomeric glycoprotein that is primarily produced by T cells and macrophages. The GM-CSF receptor is expressed on different immune cells (monocytes, macrophages, and DCs) and also on other cells. It was shown already in 2001 that genetic depletion or pharmacological blockade of GM-CSF in mice led to resistance to, or significant amelioration of, EAE. 10 Recent studies with cell-type-specific knockout mice have shown that EAE pathogenesis is critically dependent on GM-CSF-stimulated CCR2 + monocytes. 58 Moreover, a transgenic induction of GM-CSF production in peripheral T H cells in mice caused spontaneous phagocyte invasion and immunopathology in the CNS. 59 Interestingly, IL-1 and more downstream IL-23 signaling is able to expand GM-CSF-producing encephalitogenic T H 17 cells, demonstrating again redundancy of different cytokines. 60 In MS patients, CD4 + T cells show increased GM-CSF production, and frequencies of GM-CSFproducing T cells are reduced by immunotherapy. 61 Furthermore, a recent phase 1b study with an anti-GM-CSF antibody in patients with RRMS or secondary progressive MS has proven its tolerability. 12 However, further studies to test its efficacy to combat MS are warranted.
Conclusion
Preclinical and clinical data provide evidence of a prominent role of cytokines in MS. Already, to date, two substances targeting a specific cytokine or its receptor-daclizumab and interferon beta-have been approved to combat the disease. However, as cytokines are often redundant in their function, development of novel therapies remains complicated. Thus, mechanistic studies are needed to further distinguish signaling pathways responsible for physiological versus pathological conditions. Nonetheless, studies targeting cytokines are ongoing and their results may offer therapeutic approaches in MS.
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